StocksFundsScreenerSectorsWatchlists
ALEC

ALEC - Alector Inc Stock Price, Fair Value and News

6.08USD+0.12 (+2.01%)Market Closed

Market Summary

ALEC
USD6.08+0.12
Market Closed
2.01%

ALEC Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

ALEC Stock Price

View Fullscreen

ALEC RSI Chart

ALEC Valuation

Market Cap

582.2M

Price/Earnings (Trailing)

-4.46

Price/Sales (Trailing)

6

Price/Free Cashflow

-3.12

ALEC Price/Sales (Trailing)

ALEC Profitability

Return on Equity

-97.19%

Return on Assets

-20.97%

Free Cashflow Yield

-32.04%

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

97.1M

Rev. Growth (Yr)

5.19%

Rev. Growth (Qtr)

66.76%

ALEC Earnings

Earnings (TTM)

-130.4M

Earnings Growth (Yr)

20.97%

Earnings Growth (Qtr)

6.84%

Breaking Down ALEC Revenue

Last 7 days

-2.3%

Last 30 days

-6.1%

Last 90 days

-25.3%

Trailing 12 Months

-5.4%

How does ALEC drawdown profile look like?

ALEC Financial Health

Current Ratio

3.18

ALEC Investor Care

Shares Dilution (1Y)

15.32%

Diluted EPS (TTM)

-1.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023125.7M102.1M96.3M97.1M
2022227.4M300.7M133.2M133.6M
202118.0M21.4M197.9M207.1M
202022.8M19.0M22.2M21.1M
201928.4M28.2M24.4M21.2M
20188.4M15.2M21.6M27.7M
20171.2M2.1M2.9M3.7M
2016000416.0K

Tracking the Latest Insider Buys and Sells of Alector Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 19, 2024
desouza errol b
acquired
-
-
41,250
-
Mar 19, 2024
altmeyer mark
acquired
-
-
41,250
-
Mar 04, 2024
grasso marc
sold
-39,561
6.9212
-5,716
chief financial officer
Mar 04, 2024
kenkare-mitra sara
sold
-70,386
6.9217
-10,169
president and head of r&d
Mar 04, 2024
rosenthal arnon
sold
-130,386
6.9218
-18,837
chief executive officer
Mar 04, 2024
romano gary
sold
-41,553
6.9245
-6,001
chief medical officer
Dec 05, 2023
garofalo elizabeth a.
gifted
-
-
-9,459
-
Dec 04, 2023
romano gary
sold
-27,994
5.56
-5,035
chief medical officer
Dec 04, 2023
rosenthal arnon
sold
-132,500
5.56
-23,831
chief executive officer
Dec 04, 2023
grasso marc
sold
-25,431
5.56
-4,574
chief financial officer

1–10 of 50

Which funds bought or sold ALEC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-96.05
-936
48.00
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
unchanged
-
60,750
323,190
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-20.55
-770,888
35,004,600
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
130
2,954,390
4,562,850
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
46,502
251,769
-%
Feb 27, 2024
Beaird Harris Wealth Management, LLC
sold off
-100
-1,018
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
4.76
2,157,000
9,590,000
-%
Feb 15, 2024
BARCLAYS PLC
added
39.19
643,000
1,542,000
-%
Feb 15, 2024
MEDICI CAPITAL LLC
added
223
1,151,560
1,538,120
1.78%
Feb 15, 2024
JANE STREET GROUP, LLC
added
69.87
439,124
841,292
-%

1–10 of 47

Are Funds Buying or Selling ALEC?

Are funds buying ALEC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALEC
No. of Funds

Unveiling Alector Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.21%
4,386,541
SC 13G/A
Feb 12, 2024
morgan stanley
5.5%
4,605,044
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
polaris venture partners vi, l.p.
0.5%
498,468
SC 13G/A
Feb 08, 2024
rosenthal arnon
-
7,285,773
SC 13G
Jan 24, 2024
blackrock inc.
9.6%
8,068,553
SC 13G/A
Oct 13, 2023
fmr llc
-
0
SC 13G/A
Oct 10, 2023
fil ltd
-
0
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
4.9%
4,056,548
SC 13G/A
Feb 10, 2023
rosenthal arnon
-
6,884,362
SC 13G/A

Recent SEC filings of Alector Inc

View All Filings
Date Filed Form Type Document
Mar 21, 2024
3
Insider Trading
Mar 21, 2024
3
Insider Trading
Mar 21, 2024
4
Insider Trading
Mar 21, 2024
4
Insider Trading
Mar 21, 2024
8-K
Current Report
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 01, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of ALEC?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Alector Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Alector Inc News

Latest updates
Defense World • 26 Mar 2024 • 08:48 am
InvestorsObserver • 20 Mar 2024 • 05:01 pm
MarketBeat • 20 Mar 2024 • 03:52 am
InvestorsObserver • 19 Mar 2024 • 06:21 pm

Alector Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue66.8%15.009.0056.0017.0014.0015.0080.0024.0014.001827.004.005.006.003.007.006.003.007.006.009.00
Operating Expenses4.9%63.0060.0060.0067.0070.0063.0070.0069.0070.0056.0062.0057.0058.0060.0050.0049.0038.0037.0034.0026.0028.00
  S&GA Expenses11.6%15.0013.0014.0015.0015.0014.0016.0016.0017.0013.0014.0011.0013.0016.0016.0015.0013.008.008.006.004.00
  R&D Expenses3.0%48.0046.0046.0052.0054.0048.0055.0053.0053.0043.0048.0046.0044.0044.0034.0035.0026.0029.0026.0021.0024.00
Income Taxes33.1%2.001.001.001.001.001.001.001.00-------------
Net Income6.8%-41.43-44.471.00-45.86-52.43-46.1510.00-44.62-55.61127-55.15-52.17-52.18-52.70-45.33-40.02-30.53-31.74-24.56-18.56-17.37
Net Income Margin8.5%-1.34*-1.47*-1.40*-1.07*-1.00*-1.02*0.12*-0.13*-0.18*-0.17*-9.90*-11.22*---------
Free Cashflow0.3%-46.30-46.45-44.22-49.57-49.69-50.97-58.19134-49.82444-45.37-53.64---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.5%622672709748788837890954815854397440488532572619422450477496308
  Current Assets-7.7%566613648686726775827891750788329375422470510556357385415442293
    Cash Equivalents-26.9%75.0010213219615418417245533151712611151.0085.0093.0016191.0087.0069.0061.0067.00
  Net PPE-5.4%22.0023.0024.0025.0026.0026.0026.0026.0027.0028.0029.0029.0030.0031.0032.0033.0034.0034.0032.0022.0011.00
Liabilities-4.3%488510512565573584601687514518213213221221217227227231232230195
  Current Liabilities14.5%17815513299.0094.0016114914314013374.0064.0068.0071.0066.0072.0062.0059.0067.0056.0048.00
Shareholder's Equity-17.5%134163196183214253289268301336185228268310355392195219246266-
  Retained Earnings-6.2%-710-668-624-625-579-527-481-490-446-390-517-462-410-357-305-259-219-189-157-132-114
  Additional Paid-In Capital1.5%84483282281179978777676274872770269067766765964941440840339917.00
Shares Outstanding0.9%85.0084.0084.0083.0083.0083.0082.0082.0080.0081.0080.0079.00---------
Float---384---627---1,193---1,376---549--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations1.0%-46,070-46,540-43,004-48,548-48,925-49,053-57,442135,091-49,265445,052-44,543-52,693-47,658-40,821-45,942-32,313-28,827-28,863-18,052-23,566-17,654
  Share Based Compensation14.7%11,54210,05910,22210,97510,96310,76612,47811,93912,70610,2019,0788,8008,9028,0306,9486,6425,2384,1043,6943,2452,660
Cashflow From Investing6.5%18,07116,961-21,81588,70118,38160,530-225,819-12,106-146,753-69,05456,591109,55311,55233,013-24,744-124,87230,05745,90926,422-151,26242,465
Cashflow From Financing-590-8811,0796364899062,4838,63814,8212,9623,8741,0962862,270228,4611,437720-116170,312-1,280

ALEC Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total revenue$ 97,062$ 133,617$ 207,085
Operating expenses:   
Research and development192,115210,418189,407
General and administrative56,68761,03355,038
Total operating expenses248,802271,451244,445
Loss from operations(151,740)(137,834)(37,360)
Other income, net26,5617,7781,031
Loss before income taxes(125,179)(130,056)(36,329)
Income tax expense5,2123,2540
Net loss(130,391)(133,310)(36,329)
Unrealized gain (loss) on marketable securities4,759(3,632)(1,557)
Comprehensive loss$ (125,632)$ (136,942)$ (37,886)
Net loss per share, basic$ (1.56)$ (1.62)$ (0.45)
Net loss per share, diluted$ (1.56)$ (1.62)$ (0.45)
Shares used in computing net loss per share, basic83,733,73082,467,58780,416,936
Shares used in computing net loss per share, diluted83,733,73082,467,58780,416,936

ALEC Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 74,555$ 154,323
Marketable securities474,306558,528
Receivable from collaboration partner02,587
Prepaid expenses and other current assets16,94610,997
Total current assets565,807726,435
Property and equipment, net21,86125,521
Operating lease right-of-use assets25,19527,811
Restricted cash1,5461,472
Other assets7,4186,409
Total assets621,827787,648
Current liabilities:  
Accounts payable3,7754,189
Accrued clinical supply costs5,2155,559
Accrued liabilities30,37827,771
Deferred revenue, current portion82,97548,231
Payable to collaboration partner7,7030
Refund liability to collaboration partner, current portion39,4400
Operating lease liabilities, current portion8,4628,059
Total current liabilities177,94893,809
Deferred revenue, long-term portion210,845443,370
Refund liability to collaboration partner, long-term portion67,0470
Operating lease liabilities, long-term portion30,45635,268
Other long-term liabilities1,373759
Total liabilities487,669573,206
Commitments and contingencies (Note 4)
Stockholders' equity:  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively88
Additional paid-in capital844,044798,696
Accumulated other comprehensive income (loss)184(4,575)
Accumulated deficit(710,078)(579,687)
Total stockholders' equity134,158214,442
Total liabilities and stockholders' equity$ 621,827$ 787,648
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.alector.com
 EMPLOYEES239

Alector Inc Frequently Asked Questions


What is the ticker symbol for Alector Inc? What does ALEC stand for in stocks?

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alector Inc (ALEC)?

As of Wed Mar 27 2024, market cap of Alector Inc is 582.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers. The fair value of Alector Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alector Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALEC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alector Inc a good stock to buy?

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

What is Alector Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, ALEC's PE ratio (Price to Earnings) is -4.46 and Price to Sales (PS) ratio is 6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.